TGW211 click-cleavable imaging for HER2-positive cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

TGW211 combines trastuzumab labeled with Indium-111 via a DOTA-TCO linker and a small-molecule tetrazine trigger to enable click-cleavable release of the radiolabel and faster clearance from normal tissues. In this early Phase 1 interventional study, adults with histologically confirmed HER2-positive solid tumors and at least one measurable lesion receive [111In]In-DOTA-TCO-trastuzumab followed by the tetrazine trigger and undergo SPECT/CT imaging to evaluate tumor-to-background ratios and pharmacokinetics. Eligible participants have ECOG 0–1 and adequate organ and marrow function so that safety and imaging performance can be monitored. Imaging time points and blood sampling are used to determine how rapidly radioactivity clears after trigger administration and to inform optimal timing for future diagnostic or therapeutic use.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signed, written informed consent and willing and able to comply with study requirements.
2. Male or Female aged ≥ 18 years.
3. Histologically confirmed HER2-positive cancer (IHC 3+ or IHC 2+ AND FISH+) with at least 1 measurable target lesion of at least 10 mm on CT or MRI based on RECIST v1.1, assessed by the investigator to enable adequate SPECT/CT imaging.
4. WHO performance status (ECOG) of 0 or 1.
5. Adequate organ and bone marrow function, evidenced by the following laboratory results:

   1. Absolute neutrophil count ≥ 1.5 x 10\^9 /l;
   2. Platelet count ≥ 100 x 10\^9 /l;
   3. Hemoglobin ≥ 9.0 g/dl or 5.6 mmol/l;
   4. Total bilirubin ≤ 1.5 x the upper limit of normal (ULN);
   5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN (or ≤ 5.0 x ULN in the presence of liver metastases);
   6. Serum creatinine ≤ 1.5 x ULN; - Estimated Glomerular Filtration Rate (eGFR)\* ≥ 60 ml/min/1.73 m2 ; \*preferably calculated with CKD-EPI formula.

Exclusion Criteria:

1. Medical history of myocardial infarction within 6 months before participation or symptomatic CHF (New York Heart Association Class III to IV).
2. QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec on screening ECG or congenital long QT syndrome.
3. Has a history of (non-infectious) ILD/pneumonitis that required steroids or has current or suspected ILD/pneumonitis.
4. Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g, pulmonary embolism within 3 months of trial participation, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc.).
5. Has an uncontrolled infection requiring systemic antibiotics, antivirals, or antifungals.
6. Participation in another clinical study with an investigational product during the past 6 weeks.
7. Concurrent enrolment in another clinical study unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study.
8. Pregnant or breastfeeding women, where pregnancy is defined as the time between conception and termination of gestation, confirmed by a positive urinary or serum pregnancy test.
9. Women of childbearing potential (WOCBP), defined as women physiologically capable of becoming pregnant and no evidence of post-menopausal status, unless they use highly effective methods of contraception or abstain from sexual activity for 30 days after investigational drug administration. Male partners of female patients should also use a condom during intercourse for 30 days after investigational drug administration to the partner to prevent them from fathering a child.
10. Male patients in the reproductive age, not willing or able to use a condom or abstain from sexual activity for 30 days after investigational drug administration. WOCBP partners of sexually active male patients should also use a highly effective contraception method during intercourse for 30 days after investigational drug administration of the partner.
11. Known allergy or hypersensitivity to any of the investigational drugs or its excipients.
12. Any condition which, in the opinion of the investigator, would preclude participation in the study.
13. Second active malignancy.

Where it's running

• Radboud University Medical Center
  Nijmegen, Gelderland, Netherlands Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment with YH32367 for HER2 Positive Advanced Solid Tumors

  This study is testing a new treatment called YH32367 to see if it can safely help people with advanced solid tumors that are HER2-positive.

  Recruiting at 15 sites Phase 1/2 Yuhan Corporation · Boston, Massachusetts and 18 other locations · NCT05523947

• How incretin treatments affect muscle mass and function in people with overweight or obesity

  This study will see how drugs like semaglutide and tirzepatide influence fat-free mass, muscle strength, and physical function in adults with overweight or obesity.

  Recruiting Radboud University Medical Center · Amsterdam and 1 other locations · NCT07929831

• Affordable, tailored physical therapy for financially vulnerable people after trauma

  We’re testing whether a patient-friendly, low-cost approach to physical therapy helps adults with trauma injuries who are financially vulnerable maintain or improve their quality of life.

  Recruiting Radboud University Medical Center · Nijmegen, Gelderland · NCT07795216

• Timing of Immunotherapy in Melanoma

  This trial tests whether starting standard melanoma immunotherapy earlier in the day (before 10 am) versus later in the day (after 1 pm) makes a difference for patients with unresectable or metastatic melanoma.

  Recruiting Radboud University Medical Center · Amsterdam and 4 other locations · NCT07696715

• Fiber to boost gut bacteria and immunotherapy response in advanced melanoma

  In people with advanced melanoma starting immunotherapy, this trial tests whether increasing dietary fiber can grow beneficial gut bacteria and improve treatment response.

  Recruiting Phase 2 Radboud University Medical Center · Nijmegen, Gelderland and 1 other locations · NCT07686835

• Exercise to Boost Immunotherapy Response in Advanced Kidney Cancer

  In this pilot study, adults with advanced renal cell carcinoma receiving first-line nivolumab plus ipilimumab will try a supervised HIIT exercise program to see if it helps them better tolerate treatment and possibly improve immune and clinical outcomes.

  Recruiting at 2 sites Radboud University Medical Center · Arnhem, Gelderland and 1 other locations · NCT07680556

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.